Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: State of the art

Robert B Diasio, Jeanne Fourie

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) is an important mediator of normal cellular processes such as growth, survival, differentiation and morphogenesis. Disturbances in the EGFR pathway have been associated with the development and progression of malignancy, including cellular proliferation, angiogenesis, invasion/metastasis and anti-apoptosis, as well as with resistance to chemotherapy and/or radiation therapy. As a result, this is an excellent rationale for treatment with EGFR-specific therapeutic agents. These agents may be EGFR-targeted antibodies or small molecules that inactivate the receptor tyrosine kinase. While only cetuximab has received US FDA approval for the treatment of colorectal cancer, numerous agents are currently in development and in clinical trials and constitute an area of intensive, ongoing research.

Original languageEnglish (US)
Pages (from-to)1441-1463
Number of pages23
JournalDrugs
Volume66
Issue number11
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Chemotherapy
Radiotherapy
Receptor Protein-Tyrosine Kinases
Therapeutics
Morphogenesis
Cell Proliferation
Clinical Trials
Apoptosis
Neoplasm Metastasis
Drug Therapy
Molecules
Antibodies
Growth
Research
Neoplasms

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Targeting the epidermal growth factor receptor in the treatment of colorectal cancer : State of the art. / Diasio, Robert B; Fourie, Jeanne.

In: Drugs, Vol. 66, No. 11, 2006, p. 1441-1463.

Research output: Contribution to journalArticle

@article{f6dab31f8eba4fe892be8e5e69713de2,
title = "Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: State of the art",
abstract = "The epidermal growth factor receptor (EGFR) is an important mediator of normal cellular processes such as growth, survival, differentiation and morphogenesis. Disturbances in the EGFR pathway have been associated with the development and progression of malignancy, including cellular proliferation, angiogenesis, invasion/metastasis and anti-apoptosis, as well as with resistance to chemotherapy and/or radiation therapy. As a result, this is an excellent rationale for treatment with EGFR-specific therapeutic agents. These agents may be EGFR-targeted antibodies or small molecules that inactivate the receptor tyrosine kinase. While only cetuximab has received US FDA approval for the treatment of colorectal cancer, numerous agents are currently in development and in clinical trials and constitute an area of intensive, ongoing research.",
author = "Diasio, {Robert B} and Jeanne Fourie",
year = "2006",
doi = "10.2165/00003495-200666110-00003",
language = "English (US)",
volume = "66",
pages = "1441--1463",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "11",

}

TY - JOUR

T1 - Targeting the epidermal growth factor receptor in the treatment of colorectal cancer

T2 - State of the art

AU - Diasio, Robert B

AU - Fourie, Jeanne

PY - 2006

Y1 - 2006

N2 - The epidermal growth factor receptor (EGFR) is an important mediator of normal cellular processes such as growth, survival, differentiation and morphogenesis. Disturbances in the EGFR pathway have been associated with the development and progression of malignancy, including cellular proliferation, angiogenesis, invasion/metastasis and anti-apoptosis, as well as with resistance to chemotherapy and/or radiation therapy. As a result, this is an excellent rationale for treatment with EGFR-specific therapeutic agents. These agents may be EGFR-targeted antibodies or small molecules that inactivate the receptor tyrosine kinase. While only cetuximab has received US FDA approval for the treatment of colorectal cancer, numerous agents are currently in development and in clinical trials and constitute an area of intensive, ongoing research.

AB - The epidermal growth factor receptor (EGFR) is an important mediator of normal cellular processes such as growth, survival, differentiation and morphogenesis. Disturbances in the EGFR pathway have been associated with the development and progression of malignancy, including cellular proliferation, angiogenesis, invasion/metastasis and anti-apoptosis, as well as with resistance to chemotherapy and/or radiation therapy. As a result, this is an excellent rationale for treatment with EGFR-specific therapeutic agents. These agents may be EGFR-targeted antibodies or small molecules that inactivate the receptor tyrosine kinase. While only cetuximab has received US FDA approval for the treatment of colorectal cancer, numerous agents are currently in development and in clinical trials and constitute an area of intensive, ongoing research.

UR - http://www.scopus.com/inward/record.url?scp=33747340480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747340480&partnerID=8YFLogxK

U2 - 10.2165/00003495-200666110-00003

DO - 10.2165/00003495-200666110-00003

M3 - Article

C2 - 16906777

AN - SCOPUS:33747340480

VL - 66

SP - 1441

EP - 1463

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 11

ER -